The impact of CFTR modulator triple therapy on type 2 inflammatory response in patients with cystic fibrosis.

Mehta, A M; Lee, I; Li, G; Jones, M K; Hanson, L; Lonabaugh, K; List, R; Borish, L; Albon, D P

Mehta, A M; Lee, I; Li, G; Jones, M K; Hanson, L; Lonabaugh, K; List, R; Borish, L; Albon, D P.

Afiliación

Mehta AM; University of Virginia School of Medicine, Charlottesville, VA, USA.
Lee I; Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
Li G; Department of Statistics, University of Virginia, Charlottesville, VA, USA.
Jones MK; Public Health Sciences, University of Virginia, Charlottesville, VA, USA.
Hanson L; University of Virginia School of Medicine, Charlottesville, VA, USA.
Lonabaugh K; Department of Medicine, University of Virginia, Charlottesville, VA, USA.
List R; Department of Medicine, University of Virginia, Charlottesville, VA, USA.
Borish L; Department of Medicine, University of Virginia, Charlottesville, VA, USA.
Albon DP; Department of Microbiology, University of Virginia, Charlottesville, USA.

Allergy Asthma Clin Immunol ; 19(1): 66, 2023 Jul 31.

Article en En | MEDLINE | ID: mdl-37525180

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Allergy Asthma Clin Immunol Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google